ABBVAbbVie
Price
+27%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: the price
Quality mixed, no red flags, demanding price, growing in the filings, the market undecided.
AbbVie or "the company" refer to AbbVie Inc., or AbbVie Inc. and its consolidated subsidiaries, as the context requires. AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.
In the company’s own words · 10-K filed Feb 20, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
AbbVie (ABBV) reported revenue of $17.0B in Q2 2026 (quarter ended Jun 30, 2026), up 10% from the same quarter a year earlier. That came with a gross margin of 75% and net income of $3.61B (21% of revenue). For the full year FY2025, revenue was $61.2B (+8.6% year on year) and net income $4.23B. Its largest product in Q2 2026 was SKYRIZI at $4.77B, 36% of the disclosed total, well ahead of RINVOQ at 13%. The next results filing is expected around Jan 6, 2027, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 5, 2026Guidance Including the Impact of Acquired IPR&D and Milestones Expense.Earnings release · press release
- Sep 3, 2026AbbVie Completes Acquisition of Apogee Therapeutics.Regulation FD disclosure · press release
- Aug 18, 2026On August 18, 2026, AbbVie Inc. (“AbbVie”) completed its previously announced underwritten public offering (the “Notes Offering”) of $500,000,000 aggregate principal amount of its senior floating rate notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of its 4.500% senior notes due …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $13.30BThe company’s own SEC segment disclosure.
- SKYRIZI$4.77B36%
- RINVOQ$1.76B13%
- Other Products$1.11B8%
- Vraylar$1.07B8%
- Botox Therapeutic$864.0M6%
- HUMIRA$425.0M3%
- Other (15)$3.30B25%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, General
The closest names by size in the same industry